Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History OCGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics OCGN

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Ocugen Inc

OCGN
Current price
1.11 USD +0.01 USD (+0.91%)
Last closed 1.14 USD
ISIN US67577C1053
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 335 835 648 USD
Yield for 12 month -41.88 %
1Y
3Y
5Y
10Y
15Y
OCGN
21.11.2021 - 28.11.2021

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. Address: 11 Great Valley Parkway, Malvern, PA, United States, 19355

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

6.50 USD

P/E Ratio

Dividend Yield

Financials OCGN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures OCGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+4 055 000 USD

Last Year

+6 036 000 USD

Current Quarter

+1 481 000 USD

Last Quarter

+764 000 USD

Current Year

+4 055 000 USD

Last Year

+5 332 000 USD

Current Quarter

+1 481 000 USD

Last Quarter

+764 000 USD
EBITDA -54 344 000 USD
Operating Margin TTM -979.14 %
Price to Earnings
Return On Assets TTM -61.33 %
PEG Ratio
Return On Equity TTM -248.97 %
Wall Street Target Price 6.50 USD
Revenue TTM 4 522 000 USD
Book Value 0.054 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 46.10 %
Dividend Yield
Gross Profit TTM -27 945 000 USD
Earnings per share -0.20 USD
Diluted Eps TTM -0.20 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation OCGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 15.22
Enterprise Value Revenue 71.65
Price Sales TTM 74.27
Enterprise Value EBITDA -1.95
Price Book MRQ 20.74

Technical Indicators OCGN

For 52 Weeks

0.52 USD 1.98 USD
50 Day MA 0.91 USD
Shares Short Prior Month 65 193 477
200 Day MA 0.83 USD
Short Ratio 11.27
Shares Short 63 212 833
Short Percent 22.69 %